October Newsletter

Posted:
12
December 2007

Gain Regulatory Approval in the UK in less than 14 Days!Calling all Sponsors!Are you concerned about Regulatory Approval timelines in the UK?Richmond Pharmacology has recently undertaken an analysis of all studies conducted in our units over the past two years and the results speak for themselves. The average approval time for Phase I studies conducted at Richmond Pharmacology since early 2006 is 13.65 days. This is in line with the MHRA's own performance metrics published on their website. If you have any questions regarding gaining regulatory approval for your study, please contact us.Conference & EventsPartnerships In Clinical Trials - 5th - 8th November, AmsterdamBook via Richmond Pharmacology and receive a 25% discount on the delegate fee!Richmond Pharmacology will be exhibiting at the Partnerships in Clinical Trials Conference, the largest gathering of clinical trials outsourcing professionals in Europe. For full details of the Conference Programme please visit the CTC websiteWe very much look forward to meeting you at this conference. If your time at the conference is limited and you wanted to arrange a time convenient for you to meet the Richmond Pharmacology team please contact Charlotte Gowling.To enter this years' most exciting prize draw to win a trip to New York, stop by booth number 15!To register and receive a 25% discount, please visit the website and enter VIP Code CQ3002RICQTc StudiesIs your QTc study putting pressure on your budget?Over the past four years, and many QTc studies later, Richmond Pharmacology has demonstrated an ever improving performance in the quality of ECG's taken at the bedside in our clinics and processed in our ECG Core Laboratory. Our statistician has reviewed all the data produced and we are consistently driving the variability of the ECG reading down to a level unparalleled in the industry. The result of this is that due to the high quality of our ECG readings you have the ability to conduct a thorough QT study (TQT) in a much smaller sample size. Recent experience has shown that Richmond Pharmacology can bring TQT budgets down by as much as 50%.To get access to world-leading Cardiologist, Prof. A.J. Camm and to discuss the study design of your TQT study with the Richmond Pharmacology QTc Specialist Team contact Charlotte Gowling.Join the Buzz surrounding conducting your TQT study at Richmond Pharmacology and meet QT Bee.Our ServicesMeet your outsourcing needs all under one roof!As the UK's largest Early Phase CRO, boasting one of the largest Volunteer Databases of over 75,000 subjects, Richmond Pharmacology is the CRO of choice amongst many of the Top 20 Pharmaceutical Companies. To discuss your Early Phase outsourcing requirements from Protocol to Report, contact Charlotte Gowling.& Finally...Feedback for free Jelly Belly Beans!Richmond Pharmacology are constantly striving to improve our services and as a result we would like to hear your views on us as a company and the services that we provide.If you are interested in taking part in a short piece of market research then please contact Helen Bayliss. We will send you a test tube of Jelly Belly Beans as a token of our gratitude.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more